Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.
Sponsor: W.L.Gore & Associates
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from W.L.Gore & Associates
Other End Stage Renal Disease trials with similar outcome
A NA clinical study on End Stage Renal Disease, this trial is terminated or withdrawn. The trial is conducted by W.L.Gore & Associates and has accumulated 10 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Jan 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Mar 2018 — Jun 2018 [monthly]
Terminated NA
-
Oct 2017 — Mar 2018 [monthly]
Terminated NA
-
Jun 2017 — Oct 2017 [monthly]
Terminated NA
Status: Enrolling By Invitation → Terminated
-
Jan 2017 — Jun 2017 [monthly]
Enrolling By Invitation NA
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- W.L.Gore & Associates
For direct contact, visit the study record on ClinicalTrials.gov .